BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 18266400)

  • 1. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
    Katayama K; Matsuno T
    Clin Drug Investig; 2008; 28(3):149-58. PubMed ID: 18266400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
    Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
    Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
    Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
    Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
    Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
    Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
    Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
    Reid DM; Adami S; Devogelaer JP; Chines AA
    Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
    Tosteson AN; Burge RT; Marshall DA; Lindsay R
    Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
    Mok CC; Tong KH; To CH; Siu YP; Ma KM
    Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of osteoporosis with bisphosphonates.
    Watts NB
    Rheum Dis Clin North Am; 2001 Feb; 27(1):197-214. PubMed ID: 11285996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
    Adami S; Isaia G; Luisetto G; Minisola S; Sinigaglia L; Silvestri S; Agnusdei D; Gentilella R; Nuti R;
    Osteoporos Int; 2008 Aug; 19(8):1219-23. PubMed ID: 18286217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
    Wells G; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
    Cochrane Database Syst Rev; 2008 Jan; (1):CD004523. PubMed ID: 18254053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
    Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
    Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of minodronic acid hydrate for the treatment of osteoporosis.
    Tanishima S; Morio Y
    Clin Interv Aging; 2013; 8():185-9. PubMed ID: 23440003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.